Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 6.2% – Should You Sell?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) fell 6.2% on Tuesday . The stock traded as low as $31.70 and last traded at $31.61. 160,447 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 513,364 shares. The stock had previously closed at $33.70.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on KYMR shares. BTIG Research assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Citigroup assumed coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective on the stock. BMO Capital Markets assumed coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price for the company. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, HC Wainwright raised their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $56.36.

Kymera Therapeutics Stock Down 0.6 %

The business has a 50-day simple moving average of $36.29 and a 200-day simple moving average of $42.00. The company has a market cap of $1.96 billion, a PE ratio of -12.91 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the transaction, the insider now directly owns 80,085 shares of the company’s stock, valued at $2,438,588.25. The trade was a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,788 shares of company stock valued at $455,202 over the last ninety days. Corporate insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares in the last quarter. State of Wyoming purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $45,000. GF Fund Management CO. LTD. acquired a new position in Kymera Therapeutics during the fourth quarter worth about $55,000. KBC Group NV grew its stake in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares in the last quarter. Finally, Quarry LP acquired a new stake in Kymera Therapeutics in the 3rd quarter valued at about $95,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.